Angiotensin Converting Enzyme in Psoriasis A comprehensive review

Abstract

Objectives: To assess the function of the enzyme angiotensin converting in psoriasis. Background: The powerful vasoconstrictor angiotensin-converting enzyme (ACE) is essential for maintaining healthy cutaneous homeostasis. Serum ACE levels have been reported to be higher in psoriasis patients in studies, indicating that this enzyme may be involved in the aetiology of psoriasis as well as preclinical atherosclerosis and hypertension. Data Sources: by looking through and scanning medical databases (Pub Med and Medscape) for information on patients with psoriasis and their blood levels of angiotensin converting enzyme. Study Selection: For inclusion, each study underwent an independent evaluation. If they met the requirements listed below, they were considered: Serum Levels of Angiotensin Converting Enzyme in Patients with Psoriasis were explored in English-language publications in peer-reviewed journals. Data Extraction: Studies were disqualified if they didn't meet the criteria for inclusion. A study's ethical permission, eligibility requirements, proper controls, adequate information, and stated assessment methods were all considered in the evaluation of the study's quality. A data collecting form was used to independently extract data from each qualifying research in order to record details about the study results we were interested in. Conclusion: With respect to nail psoriasis, plaque psoriasis, psoriatic arthritis, and scalp psoriasis, no significant changes were found. However, there is a higher level of serum ACE among psoriasis patients, and these individuals have a much lower proportion of ACE.